此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

健康年轻人的色氨酸代谢

2026年9月29日 更新者:Glenda Courtney-Martin、The Hospital for Sick Children

健康年轻人对分级色氨酸摄入量的色氨酸代谢:一项试点研究

Tryptophan is an essential amino acid needed for growth and bodily functions. It is used to make serotonin which is needed for the brain to develop and function properly. However, when the body is stressed, tryptophan is broken down into compounds that can cause harm to the brain. Premature babies who get nutrition through their vein [i.e. total parenteral nutrition (TPN)] can experience this type of stress. The amount of tryptophan in TPN solutions is much higher than what premature babies need and can produce too much harmful compounds. So, it is important to study the amount of these compounds made from tryptophan. But there are no methods available to study this. Therefore, the goal of this study is to develop a method to measure the compounds made from tryptophan breakdown in adults so that it can be used for preterm babies on TPN later.

研究概览

地位

完全的

条件

详细说明

Tryptophan is an essential amino acid and must be obtained from the diet. In addition to its essential role in protein synthesis, tryptophan has diverse and complex physiological functions via various metabolic pathways. Two primary metabolic pathways include the kynurenine and serotonin pathways. Tryptophan is the only precursor for both the kynurenine and serotonin pathways. Since these two pathways share tryptophan as the common nitrogenous substrate, a competition between these pathways is demonstrated. This can result in serotonin deficiency when kynurenine pathway is activated and may contribute to the pathophysiology of developing neurological disease. Furthermore, metabolites of the kynurenine pathway can exert neurotoxic effects because they can cross the blood brain barrier to reach the central nervous system (CNS). Evidence thus far indicates that the contribution of the different pathways of tryptophan metabolism can differ based on the physiological and pathological status. However, there is no clear evidence of whether the kynurenine pathway takes precedence over synthesis of protein (for growth) or serotonin during immune activation. There are also no investigations examining the impact of tryptophan intake during immune activation, for the purposes of this study meaning any activity by the immune system, on the production of neurotoxic metabolites of the kynurenine pathway.

Tryptophan uptake from parenteral nutrition fed to preterm neonates with current amino acid solutions may be about 2-2.5 times the estimated requirement based on data from neonatal piglets. Long-term effects of this excess intake in this vulnerable population are unknown. The potential adverse effects of increased catabolism via the kynurenine pathway during stress on growth and neurodevelopment of hospitalized preterm infants has not been explored. A method to quantify the partitioning of tryptophan between the different pathways will be highly beneficial but has not been established in humans. This will enable studies in parenterally fed neonates to assess whether tryptophan concentrations in current commercial amino acid solutions produce toxic metabolites or serotonin deficiency, which can contribute to neurocognitive deficits seen in this population.

研究类型

介入性

注册 (实际的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G 1E8
        • The Hospital for Sick Children

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Consent provided
  2. Aged 18 to 45 years old (inclusive)
  3. In good general health as evidenced by medical history, physical health and biochemistry
  4. Fasting blood glucose, hemoglobin A1c (HbA1c), urea, creatinine and CRP levels within normal ranges for age.

Exclusion Criteria:

  1. Presence of chronic disease and/or acute illness known to affect protein/amino acid metabolism (e.g. HIV, diabetes, cancer, liver or kidney disease, neurological conditions including depression and anxiety, hypo- / hyperthyroidism, inflammatory conditions,, anemia, acute cold or flu)
  2. Taking medications known to affect protein/AA metabolism (e.g. steroids, anti-inflammatory medications, acetaminophen, selective serotonin reuptake inhibitors (SSRI))
  3. Inability to tolerate the diet (i.e. allergy)
  4. Significant weight loss during the past month or consumption of weight reducing diets.
  5. Significant caffeine consumption (>2 cups per day)
  6. Significant consumption of alcohol (>1 drink per day i.e. 1 beer or ½ glass of wine).
  7. Unwilling to have blood drawn from a venous access or using a ventilated hood indirect calorimeter for the purposes of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental: Tryptophan in healthy young adults (18-45 years)

Tryptophan intake levels, up to 5 levels, will be tested in a random order in all subjects

There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1. Levels of tryptophan intake will depend on [15N2]tryptophan dose.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Steady state
大体时间:10 hours

Time at which plasma and urine enrichment of L-[15N2]tryptophan reaches steady-state.

10 hours
Fractional Synthesis Rate (FSR) of tryptophan metabolites
大体时间:10 hours

Enrichment of L-[15N2]tryptophan and its metabolites (15N2-L-kynurenine, 15N-kynurenic acid, 15N-quinolinic acid, 15N2-serotonin and 15N-5-hydroxyindole acetic acid) in plasma and urine following orally administered tracer, L-[15N2]tryptophan.

10 hours

次要结果测量

结果测量
措施说明
大体时间
Partitioning of tryptophan metabolism
大体时间:10 hours

Partitioning of tryptophan between kynurenine and serotonin pathway at tryptophan intake below and above requirements

10 hours
Fractional synthesis rate (FSR)
大体时间:10 hours

Fractional synthesis rate (FSR) of metabolites of tryptophan (15N2-L-kynurenine, 15N-kynurenic acid, 15N-quinolinic acid, 15N2-serotonin and 15N-5-hydroxyindole acetic acid) at isotopic steady state

10 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Glenda Courtney-Martin, PhD, RD、The Hospital for Sick Children

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月1日

初级完成 (实际的)

2025年7月31日

研究完成 (实际的)

2025年7月31日

研究注册日期

首次提交

2024年8月8日

首先提交符合 QC 标准的

2024年8月9日

首次发布 (实际的)

2024年8月13日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅